Fierce Pharma

FEBRUARY 1, 2024

With Merck reporting a whopping $25 billion sales haul for | With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world’s top-selling drug in 2023. Keytruda looks set to take over the top spot from Pfizer and BioNTech’s Comirnaty, which ruled the previous two years, scoring sales of $55.9 billion in 2022 and $55.1 billion in 2021.

Sales 285

Sales 285

MedCity News

FEBRUARY 1, 2024

Despite Cigna and Humana ditching their pursuits to combine in December, one industry expert believes there’s still a chance after Cigna announced its plan to sell its Medicare Advantage business to Health Care Service Corp.

Sales 118

Sales 118

Fierce Pharma

FEBRUARY 1, 2024

Even after the acquisitions of Prometheus and Acceleron, Merck is ready to make more deals in the $1 to $15 billion range, according to CEO Rob Davis.

Marketing 291

Marketing 291

MedCity News

FEBRUARY 1, 2024

To meet evolving consumer expectations, providers must have a strong digital marketing strategy and user experience online. Here are 5 healthcare marketing trends to pay attention to in 2024.

Retail 110

Retail Marketing Healthcare Healthcare 110

Advertisement

Distribution

Fierce Pharma

FEBRUARY 1, 2024

Despite litigation and denouncements from the biopharma industry, Medicare price negotiations under the Inflation Reduction Act are rolling on. | Despite litigation and denouncements from the biopharma industry, Medicare price negotiations under the Inflation Reduction Act are rolling on. And today, the government is sending out its first round of offers on affected drugs.

Biopharma 256

Biopharma Government 256

MedCity News

FEBRUARY 1, 2024

Protagonist Therapeutics’ rusfertide could have preliminary data next year from its Phase 3 test in polycythemia vera. If the peptide drug wins FDA approval in this rare blood disorder, the partners will share in U.S. commercialization while Takeda is responsible for the drug in the rest of the world.

FDA 105

FDA Pharmaceutical Biopharma Pharma 105

Integrity Solutions

FEBRUARY 1, 2024

Is sales still a viable profession today? Is it something needed or that people even want to do? Many who are currently in sales positions or are considering a role in sales are beginning to question what the job really means today and whether it’s one they can be proud of — especially when it feels like their whole purpose can feel like it’s to pressure or coerce buyers into doing something.

Sales 106

Sales Training B2B Sales Sales process 106

Fierce Pharma

FEBRUARY 1, 2024

As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023. Despite a sharp decline in COVID-related sales, the company was able to grow overall revenues | As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023. Despite a sharp decline in COVID-related sales, the company was able to grow overall revenues thanks in large part to the performance of eye disease drug Vabysmo.

Sales 234

Sales Pharma 234

pharmaphorum

FEBRUARY 1, 2024

A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), although the company says there are encouraging “signals of efficacy” in the data.

Patients 103

Patients 103

Fierce Pharma

FEBRUARY 1, 2024

After GSK spent the latter half of 2023 warding off concerns about the swelling Zantac product liability litigation, the company is back at the settlement table in 2024. | After GSK spent the latter half of 2023 warding off concerns about the swelling Zantac product liability litigation, the company is back at the settlement table in 2024.

223

223

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

FEBRUARY 1, 2024

There’s a common belief in the healthcare industry that partnering with Group Purchasing Organizations (GPOs) means that most or all non-clinical purchases are covered by the contract. It almost sounds too good to be true: GPOs have all the answers for all your procurement needs. Finally, a one-stop shop for all your procurement solutions! Unfortunately, this is far from reality.

Healthcare 98

Healthcare Healthcare Management Marketing 98

Fierce Pharma

FEBRUARY 1, 2024

Despite the recent loss of exclusivity on Takeda's ADH | As Vyvanse generics take a chunk out of Takeda's sales, the company is hopeful its roster of new drugs, including its dengue fever vaccine Qdenga, can keep revenues intact.

Sales 214

Sales 214

MedCity News

FEBRUARY 1, 2024

Prior authorization software startup Cohere Health raised $50 million on Thursday, bringing its total funding to $106 million. The need for software to streamline the prior authorization process is perhaps more evident than ever given CMS’ new rule on the matter.

97

97

Fierce Pharma

FEBRUARY 1, 2024

Cultivating Connections: Continuity in Patient Engagement | 4 Ways to Bring Greater Precision to Oncology Omnichannel Experiences

Patients 164

Patients 164

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Copyright Clearance Center

FEBRUARY 1, 2024

February 1, 20 24 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announces that its President and CEO, Tracey Armstrong , was named a winner of the 2024 BIG Innovation Award recognizing organizations, products, and people bringing new ideas to life in innovative ways and presented by Business Intelligence Group.

Leads 98

Leads Management 98

Fierce Pharma

FEBRUARY 1, 2024

“We have a vision, which is to close the gap between scientific knowledge and clinical practice.” | Experienced healthcare communications expert and MD of MedThink Communications John Kane discusses the importance of physician knowledge of the patient’s psychosocial status on treatment plans and outcomes.

Physicians 130

Physicians Healthcare Healthcare 130

MedCity News

FEBRUARY 1, 2024

Coordination of benefits is a critical pillar of the Medicaid program as it ensures the efficient use of resources, prevents overutilization, promotes equity in resource distribution, mitigates fraud and abuse, contributes to program longevity and ultimately enhances healthcare access for beneficiaries.

Distribution 94

Distribution Healthcare Healthcare 94

Fierce Pharma

FEBRUARY 1, 2024

Takeda paid $300 million upfront to license a blood disorder candidate. Lonza will close a biologics plant in China. A U.S. draft bill targets several Chinese biotech companies. And more. | Takeda paid $300 million upfront to license a blood disorder candidate. Lonza will close a biologics plant in China. A U.S. draft bill targets several Chinese biotech companies.

Pharma 130

Pharma 130

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

Impetus Digital

FEBRUARY 1, 2024

Register for one of Impetus’ upcoming webinars between February 26-28: Top-5 Trends in Virtual KOL Engagement About the webinar We’re taking a look at the top trends from 2023 and share our predictions for the new year. Our expert speakers will share their unique industry insights and the “best of the best” virtual collaboration and insight-gathering programs from 2023.

Professional Services 97

Professional Services Education Healthcare Provider Patients 97

Copyright Clearance Center

FEBRUARY 1, 2024

Legislation often lags technological advances. The EU's Digital Single Market Copyright Directive leaves many open questions regarding AI text- and data-mining.

Marketing 95

Marketing 95

MedCity News

FEBRUARY 1, 2024

The more pharma companies do to become service providers in the personalized medicine era, the more they’ll succeed and the more lives they’ll help to save.

Medicine 93

Medicine Pharma Healthcare Healthcare 93

Pharmaceutical Technology

FEBRUARY 1, 2024

Merck & Co (MSD) has reported a 1% revenue increase from 2022, and may face setbacks in the next few years from top-selling drugs.

104

104

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

European Pharmaceutical Review

FEBRUARY 1, 2024

Positive results from the first global study for chimeric antigen receptor (CAR)-antologous T cell (BCMA CAR T) injection (Equecabtagene Autoleucel) in immune-mediated necrotising myopathy (IMNM), suggest that the cell therapy could provide a new therapeutic option for antibody-mediated autoimmune disorders. the cell therapy could provide a new therapeutic option for antibody-mediated autoimmune disorders” IMNM is an autoimmune-mediated skeletal muscle disorder belonging to an idiopathic i

Safety 85

Safety Patients Medical Pharmaceutical 85

pharmaphorum

FEBRUARY 1, 2024

Almirall has formed a three-year alliance with Microsoft designed to accelerate the discovery and development of personalised dermatology therapies.

89

89

Pharmaceutical Technology

FEBRUARY 1, 2024

Novartis has announced net income soaring by 62% to $8.6bn for the full year 2023 (FY 2023) from the previous year’s $6.04bn.

98

98

PharmaTimes

FEBRUARY 1, 2024

Tumours with high mtDNA mutations more likely to respond to Opdivo

Patients 113

Patients 113

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

pharmaphorum

FEBRUARY 1, 2024

Takeda licenses late-stage polycythemia vera drug candidate rusfertide from Protagonist Therapeutics, adding to its rare blood disorder pipeline.

77

77

PharmaTimes

FEBRUARY 1, 2024

Prescriptions ordered via the app are expected to save around 1.

Prescription 100

Prescription Healthcare Healthcare 100

PM360

FEBRUARY 1, 2024

Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis. According to a McKinsey report , a startling 40% of biopharma products fail to meet their sales forecasts within the initial two years, prompting a critical reassessment of strategies for product launc

Biopharma 59

Biopharma Competition Prescription Education 59

PharmExec

FEBRUARY 1, 2024

DELFI-Tumor Fraction assay was developed to improve noninvasive assessment of tumor burden and monitoring of treatment efficacy and resistance in patients with advanced cancers.

Patients 52

Patients 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management